Can semaglutide (Ozempic) cause vertigo as an adverse effect?

Dizziness is a Recognized Adverse Effect of Semaglutide

Yes, semaglutide (Ozempic) can cause dizziness as an adverse effect, though it occurs relatively infrequently. According to the FDA prescribing information, dizziness is explicitly listed among adverse reactions with a frequency >0.4% 1.

Evidence from FDA Drug Labeling

The official Ozempic prescribing information clearly identifies dizziness as a documented adverse reaction 1. This appears alongside other common side effects including:

• Fatigue
• Dysgeusia (altered taste)
• Gastrointestinal symptoms (nausea, vomiting, diarrhea)

The FDA labeling represents the most authoritative source for established adverse effects, as it reflects comprehensive safety data from clinical trials.

Clinical Guidelines Perspective

Multiple expert consensus guidelines acknowledge dizziness as part of the adverse effect profile for GLP-1 receptor agonists:

• The 2020 ACC Expert Consensus lists "nausea, vomiting, diarrhea, headache, weakness, or dizziness" as adverse effects to monitor with GLP-1RAs 2
• The 2023 obesity management guidelines from South/Southeast Asia similarly document dizziness among common side effects of semaglutide 2.4 mg 3

Emerging Evidence on Vestibular Effects

Recent real-world data suggests a more concerning pattern beyond simple dizziness. A 2025 study analyzing the TriNetX database found semaglutide users had significantly increased risk of vestibular disorders compared to controls 4:

• Hazard ratios ranged from 4.02 at 6 months to 4.95 at 3 years
• Cumulative incidence: 0.12% at 6 months increasing to 0.41% at 3 years
• Higher risk compared to tirzepatide (another GLP-1 agonist)

Another 2024 analysis of FDA adverse event data identified 203 reports of vertigo among 97,237 total adverse events with GLP-1RAs, with positional vertigo specifically noted 5.

Clinical Implications

When patients report dizziness on semaglutide, consider:

1. Timing relative to dose escalation - Most adverse effects occur during titration 2, 3

2. Distinguish between types:

   • Simple lightheadedness (more common, often related to nausea/dehydration)
   • True vertigo (spinning sensation - may indicate vestibular involvement)
   • Orthostatic symptoms (check for volume depletion from GI side effects)

3. Rule out hypoglycemia - Particularly if used with insulin or sulfonylureas, though less likely with semaglutide monotherapy 1

4. Assess for dehydration - GI side effects (nausea, vomiting, diarrhea) can lead to volume depletion and secondary dizziness

5. Monitor for vestibular symptoms - Given emerging evidence, persistent or severe vertigo warrants evaluation 4, 6

Management Approach

• Slow dose titration helps mitigate adverse effects 2, 3
• Ensure adequate hydration, especially during GI symptoms
• If dizziness is severe or persistent, consider holding dose escalation or reducing dose
• For true vestibular symptoms (vertigo, autophony, aural fullness), consider ENT referral as these may represent eustachian tube dysfunction from rapid weight loss 6

The frequency of dizziness appears relatively low based on clinical trial data, but real-world surveillance suggests vestibular effects may be more common than initially recognized, particularly with longer-term use.